ProSavin: Difference between revisions
Jump to navigation
Jump to search
m (Protected "ProSavin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)) |
||
| Line 10: | Line 10: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
[[Category:drugs]] | [[Category:drugs]] | ||
Latest revision as of 14:02, 6 September 2012
ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's Disease. It is administered to the striatum in the brain, inducing production of dopamine.[1]
It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's.[2]
Mechanism of Action
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[3]
See also
References
- ↑ Oxford BioMedica. Drug Information Page. Retrieved on March 29, 2007.
- ↑ Daily Telegraph. Investor Information. Retrieved on March 29, 2007.
- ↑ Oxford BioMedica . Drug Advanced Information Page. Retrieved on April 5, 2007.